相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of novel small molecules targeting core clock proteins to regulate circadian rhythm
Ibrahim Halil Kavakli et al.
CURRENT OPINION IN CHEMICAL ENGINEERING (2022)
CRY1-CBS binding regulates circadian clock function and metabolism
Sibel Cal-Kayitmazbatir et al.
FEBS JOURNAL (2021)
The effects of P-glycoprotein inhibitor zosuquidar on the sex and time-dependent pharmacokinetics of parenterally administered talinolol in mice
Zeliha Pala Kara et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Circadian Mechanisms in Medicine
Ravi Allada et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A CLOCK-binding small molecule disrupts the interaction between CLOCK and BMAL1 and enhances circadian rhythm amplitude
Yagmur Umay Doruk et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Variants ofcarboxylesterase 1have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients
Natsumi Matsumoto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Population Pharmacokinetic Model -Based Evaluation of Circadian Variations in Plasma 5-Fluorouracil Concentrations During Long-Term Infusion in Rats: A Comparison With Oral Anticancer Prodrugs
Shinji Kobuchi et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Phase I pharmacological study of continuous chronomodulated capecitabine treatment
Jeroen Roosendaal et al.
PHARMACEUTICAL RESEARCH (2020)
Human CRY1 variants associate with attention deficit/hyperactivity disorder
O. Emre Onat et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Necdin regulates BMAL1 stability and circadian clock through SGT1-HSP90 chaperone machinery
Renbin Lu et al.
NUCLEIC ACIDS RESEARCH (2020)
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
John N. Primrose et al.
LANCET ONCOLOGY (2019)
Circadian control of stress granules by oscillating EIF2α
Ruiqi Wang et al.
CELL DEATH & DISEASE (2019)
High-throughput method to analyze tegafur and 5-fluorouracil in human tears and plasma using hydrophilic interaction liquid chromatography/tandem mass spectrometry
Ritsuko Shiokawa et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2019)
Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity - implications for mechanistic pharmacokinetics modeling
Alper Okyar et al.
SCIENTIFIC REPORTS (2019)
Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats
Shinji Kobuchi et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Molecular Aspects of Circadian Pharmacology and Relevance for Cancer Chronotherapy
Narin Ozturk et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
The Photolyase/Cryptochrome Family of Proteins as DNA Repair Enzymes and Transcriptional Repressors
Ibrahim Halil Kavakli et al.
PHOTOCHEMISTRY AND PHOTOBIOLOGY (2017)
Mutation of the Human Circadian Clock Gene CRY1 in Familial Delayed Sleep Phase Disorder
Alina Patke et al.
CELL (2017)
Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats
Shinji Kobuchi et al.
XENOBIOTICA (2016)
Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study
Kezban Nur Pilanci et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion
Gini F. Fleming et al.
BMC CANCER (2015)
Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer A Phase II Study
Emilio Bajetta et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2014)
Circadian gene variants in cancer
Nicole M. Kettner et al.
ANNALS OF MEDICINE (2014)
Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study
Zuleyha Akgun et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice
Seng Chuan Tang et al.
CLINICAL CANCER RESEARCH (2014)
Dual modes of CLOCK:BMAL1 inhibition mediated by Cryptochrome and Period proteins in the mammalian circadian clock
Rui Ye et al.
GENES & DEVELOPMENT (2014)
A Novel BHLHE41 Variant is Associated with Short Sleep and Resistance to Sleep Deprivation in Humans
Renata Pellegrino et al.
SLEEP (2014)
Starvation, detoxification, and multidrug resistance in cancer therapy
Changhan Lee et al.
DRUG RESISTANCE UPDATES (2012)
Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma
Akiko Kuwahara et al.
International Journal of Medical Sciences (2012)
Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans - toxicological implications
Hidetoshi Shindoh et al.
JOURNAL OF TOXICOLOGICAL SCIENCES (2011)
Circadian Timing in Cancer Treatments
Francis Levi et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
The Mammalian Circadian Timing System: Organization and Coordination of Central and Peripheral Clocks
Charna Dibner et al.
ANNUAL REVIEW OF PHYSIOLOGY (2010)
Polyphenol contents and antioxidant activity of lyophilized aqueous extract of propolis from Erzurum, Turkey
Ilhami Gulcin et al.
FOOD AND CHEMICAL TOXICOLOGY (2010)
Circadian Expression Profiles of Drug-Processing Genes and Transcription Factors in Mouse Liver
Yu-Kun Jennifer Zhang et al.
DRUG METABOLISM AND DISPOSITION (2009)
Implications of circadian clocks for the rhythmic delivery of cancer therapeutics
Francis Levi et al.
ADVANCED DRUG DELIVERY REVIEWS (2007)
Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients:: phase II study
Daniele Santini et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Circadian rhythms: Mechanisms and therapeutic implications
Francis Levi et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2007)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver:: comparison between enzyme activity and gene expression
B Porsin et al.
EUROPEAN JOURNAL OF CANCER (2003)
Clinical pharmacokinetics of capecitabine
B Reigner et al.
CLINICAL PHARMACOKINETICS (2001)
分享论文
